BBOT
NASDAQ · Biotechnology
Bridgebio Oncology Therapeut
$7.89
+0.03 (+0.38%)
Open$7.87
Previous Close$7.86
Day High$7.90
Day Low$7.76
52W High$14.87
52W Low$7.60
Volume—
Avg Volume352.8K
Market Cap629.69M
P/E Ratio133.48
EPS$0.20
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+446.3% upside
Current
$7.89
$7.89
Target
$43.10
$43.10
$22.76
$43.10 avg
$48.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 230.06M | 225.69M | 230.96M |
| Net Income | 46.84M | 61.14M | 59.73M |
| Profit Margin | 20.4% | 27.1% | 25.9% |
| EBITDA | 108.29M | 111.55M | 110.87M |
| Free Cash Flow | 56.78M | 36.61M | 55.99M |
| Rev Growth | -2.3% | +22.3% | +7.3% |
| Debt/Equity | 0.31 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |